AM6

Amicus Therapeutics INC

+$226.4M

Net Activity

Institutions Holding

296

Popularity Rank

#2009

Avg Weight

0.35%

Total Value

$4.8B

Ownership Trend

296 institutions currently hold AM6, with 153 net buyers and 175 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Neutral

Based on recent trading activity

Net Selling Institutions

175

Net Buying Institutions

153

Key Holders

View all 296 holding institutions

Quarterly Activity

Recent Activity

+$3.3B

Total Buy Value

$9.4B

Total Sell Value

New buy46
Trim92
Add107
Sold out83

153

Net Buyers

175

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding AMICUS THERAPEUTICS INC (AM6)?
Major stakeholders currently include BlackRock, Inc. ($489.9M), UBS Group AG ($230.8M), Vanguard Capital Management LLC ($202.8M). Based on the latest 13F filings, there are a total of 296 tracked investment funds and institutions maintaining positions in AM6.
What is the overall institutional sentiment toward AM6 recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $226.4M, driven by 153 managers accumulating shares while 175 reduced their exposure.
Which institutions have been selling or reducing their AM6 positions?
In the latest period, 92 funds trimmed their holdings, and 83 managers completely exited their positions. The aggregate reported sell value was $9.4B.
Are there any notable investors adding AM6 to their portfolios?
Yes, buying activity remains notable. 46 institutions opened new positions in {ticker}, and 107 existing holders added to their shares. The total reported buy value for the quarter amounted to $3.3B.

Related Stocks